Open Access<p>Metabolic Risk Factors and Cardiovascular Safety in Ketamine Use for Treatment Resistant Depression</p>
Author(s) -
Joanna Szarmach,
Wiesław Jerzy Cubała,
Adam Włodarczyk,
Maria GałuszkoWęgielnik
Publication year - 2020
Publication title -
neuropsychiatric disease and treatment
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.819
H-Index - 67
eISSN - 1178-2021
pISSN - 1176-6328
DOI - 10.2147/ndt.s273287
Subject(s) - medicine , tolerability , ketamine , major depressive disorder , blood pressure , concomitant , mood , antidepressant , depression (economics) , population , mood disorders , anesthesia , adverse effect , psychiatry , anxiety , environmental health , hippocampus , economics , macroeconomics
Ketamine exhibits antidepressant properties in treatment-resistant depression (TRD) with some concern over its cardiovascular safety and tolerability issues. This paper reports on the cardiovascular safety in short-term intravenous ketamine treatment in TRD inpatients with major depressive disorder (MDD) and bipolar disorder (BP).